Erasca, Inc.
NASDAQ: ERAS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan E. Lim
- Employees
- 103
- Headquarters
- San Diego, United States
- IPO year
- 2021
- Market cap
- $4.3B
- Website
- https://www.erasca.com
Loading ERAS…
Loading profile data…Frequently asked questions about ERAS
What does Erasca, Inc. (ERAS) do?
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to addres...
Where does ERAS trade?
Erasca, Inc. (ERAS) trades on the NASDAQ Global Select.
What sector is ERAS in?
Erasca, Inc. (ERAS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Erasca, Inc.?
Jonathan E. Lim is the chief executive officer of Erasca, Inc. (ERAS).
Where is Erasca, Inc. headquartered?
Erasca, Inc. is headquartered in United States.
Does ERAS pay a dividend?
Erasca, Inc. (ERAS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ERAS go public?
Erasca, Inc. (ERAS) completed its initial public offering in 2021.